ID Biomedical provides update on application for court approval of acquisition by GlaxoSmithKline
2005年12月5日 - 11:15PM
PRニュース・ワイアー (英語)
VANCOUVER, Dec. 5 /PRNewswire-FirstCall/ -- ID Biomedical
Corporation (TSX: IDB; NASDAQ: IDBE) ("ID Biomedical") announced
today that it has applied to the British Columbia Supreme Court for
approval of the proposed acquisition of ID Biomedical by
GlaxoSmithKline plc. and GlaxoSmithKline Inc. The Court has
reserved its decision and indicated it expects to issue a decision
at 9:00 am (Vancouver time) on December 6, 2005. ID Biomedical also
announced that the proposed transaction has now received the
required approvals under the Investment Canada Act. Completion of
the proposed transaction remains subject to a number of conditions.
ID Biomedical expects the transaction to be completed by the end of
2005. About ID Biomedical ID Biomedical is an integrated
biotechnology company dedicated to the development of innovative
vaccine products. It operates in research, development,
manufacturing, sales and marketing from its facilities in Canada
and in the United States. ID Biomedical is dedicated to becoming a
premier vaccine company with significant marketed products
worldwide and an extensive pipeline in both clinical and
preclinical development. ID Biomedical has a leading position in
the Canadian influenza market. It received a ten year mandate from
the Government of Canada in 2001 to assure a state of readiness in
the case of an influenza pandemic and provide influenza vaccine for
all Canadians in such an event. It also currently supplies
approximately 75% of the Canadian government's influenza vaccine
purchases. The information in this news release contains so-called
"forward-looking" statements. These include statements regarding ID
Biomedical's expectations and plans relating to the interaction of
the vaccine business acquired from Shire, statements about ID
Biomedical's expectations, beliefs, intentions or strategies for
the future, which may be indicated by words or phrases such as
"anticipate", "expect", "intend", "plan", "will", "we believe", "ID
Biomedical believes", "management believes", and similar language.
All forward-looking statements are based on ID Biomedical's current
expectations and are subject to risks and uncertainties and to
assumptions made. Important factors that could cause actual results
to differ materially from those expressed or implied by such
forward-looking statements include: (i) the company's ability to
successfully complete the proposed GlaxoSmithKline transaction;
(ii) the company's ability to successfully complete preclinical and
clinical development of its products; (iii) the company's ability
to manufacture its products; (iv) the seasonality of the
flu-vaccine business and related fluctuations in the company's
revenues from quarter to quarter; (v) decisions, and the timing of
decisions, made by the health regulatory agencies regarding
approval of its products for human testing; (vi) the company's
ability to enter into distribution agreements for its products, and
to complete and maintain corporate alliances relating to the
development and commercialization of its technology and products;
(vii) market acceptance of its technologies and products; and
(viii) the competitive environment and impact of technological
change and other risks detailed in the company's filings with the
Securities and Exchange Commission. ID Biomedical bases its
forward- looking statements on information currently available to
it, and assumes no obligation to update them. For further
information, please contact: Investor Relations/Media Dean Linden
Michele Roy (604) 431-9314 (450) 978-6313 DATASOURCE: ID Biomedical
Corporation CONTACT: Investor Relations, Media, Dean Linden, (604)
431-9314, ; Michele Roy, (450) 978-6313, ; To request a free copy
of this organization's annual report, please go to
http://www.newswire.ca/ and click on Tools for Investors.
Copyright